000078930 001__ 78930
000078930 005__ 20231023123339.0
000078930 0248_ $$2sideral$$a111136
000078930 0247_ $$2doi$$a10.25107/2474-1647
000078930 037__ $$aART-2019-111136
000078930 041__ $$aeng
000078930 100__ $$aPañella, C.
000078930 245__ $$aHypersaline infusion protocol through the portal vein may focus electroporation on tumor tissue, but is it really safe? Ppreliminary results
000078930 260__ $$c2019
000078930 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078930 5203_ $$aIntroduction: irreversible Electroporation (IRE) is highly dependent on the electrical conductivity of the tissue and the high conductivity of tumor tissue, which leads to a lower field than that in the surrounding healthy tissue. Hypersaline Infusion (HI) through the portal vein focuses IRE on scattered liver tumors, by creating a differential conductivity between the different types of tissue. The aim of this study is to determine the effects of the HI protocol on the hepatic and histological biochemical results. Methods: Ten male Sprague Dawley rats were used for HI protocol. Blood samples were collected at pre-, immediately post-, 24-hrs, 72-hrs, 1- week and 3-weeks post-HI. All the animals were sacrificed after a one-month follow-up in order to collect histological samples. Results: The mortality rate in this procedure reached 30% (3/10). Only the pH and transaminases at 24-hrs were significantly and directly linked to mortality (p=0.036 and p=0.004, respectively). The three non-surviving animals had a four-time higher AST level at 24-hrs. Natremianormalized at 24-hrs post-HI. Statistically significant differences were found in hepatic necrosis between the non-surviving (n=3) and surviving rats (n=7) (30.67 ± 10.97 vs. 2.86 ± 7.56% respectively, p=0.01). Discussion: HI through the portal system involves a significant risk of possibly lethal cytolysis and acidosis. Therefore, compensatory measures and a reduced saline overload are warranted to improve the survival rates.
000078930 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000078930 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000078930 700__ $$aMoll, X.
000078930 700__ $$aQuesada, R.
000078930 700__ $$aVillanueva, A.
000078930 700__ $$aIglesias, M.
000078930 700__ $$aAndaluz, A.
000078930 700__ $$0(orcid)0000-0002-1284-9007$$aLucía, O.$$uUniversidad de Zaragoza
000078930 700__ $$aSánchez-Velázquez, P.
000078930 700__ $$aGrande, L.
000078930 700__ $$aBurdío, F.
000078930 7102_ $$15008$$2785$$aUniversidad de Zaragoza$$bDpto. Ingeniería Electrón.Com.$$cÁrea Tecnología Electrónica
000078930 773__ $$g4, 1 (2019), 2335 [5 pp.]$$pClin. surg.$$tClinics in Surgery$$x2474-1647
000078930 85641 $$uhttp://www.clinicsinsurgery.com/pdfs_folder/cis-v4-id2335.pdf$$zTexto completo de la revista
000078930 8564_ $$s16326554$$uhttps://zaguan.unizar.es/record/78930/files/texto_completo.pdf$$yVersión publicada
000078930 8564_ $$s112954$$uhttps://zaguan.unizar.es/record/78930/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000078930 909CO $$ooai:zaguan.unizar.es:78930$$particulos$$pdriver
000078930 951__ $$a2023-10-23-12:20:20
000078930 980__ $$aARTICLE